Sustained hepatitis C virus RNA clearance accompanied by elevation of hepatitis B virus DNA after short-term peginterferon-α, ribavirin and simeprevir therapy in a chronic hepatitis patient having dual infection with hepatitis B and C viruses

Kanzo/Acta Hepatologica Japonica

Volumn 56, Issue 8, 2015, Pages 422-427

  Kimura, H ^a   Ohkawa, Kazuyoshi ^a   Sakakibara, M ^a   Imanaka, K ^a   Matsunaga, T ^a   Miyazaki, M ^b   Miyagi, T ^c   Tatsumi, T ^c   Hiramatsu, N ^c   Takehara, T ^c   Katayama, K ^a  

^a OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

^b OSAKA POLICE HOSPITAL   (Japan)

^c OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Dual infection with hepatitis B and C viruses; Hepatitis B virus; Hepatitis C virus; Interferon; Viral reappearance

Indexed keywords

ENTECAVIR; PEGINTERFERON ALPHA; RIBAVIRIN; SIMEPREVIR; VIRUS DNA; VIRUS RNA;

ARTICLE; CASE REPORT; CHRONIC HEPATITIS; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HUMAN; MIXED INFECTION; VIRAL CLEARANCE; VIRUS REACTIVATION;

EID: 84940366341     PISSN: 04514203     EISSN: 18813593     Source Type: Journal    
DOI: 10.2957/kanzo.56.422     Document Type: Article

References (12)

1. Liu CJ. Treatment of patients with dual hepatitis C virus and hepatitis B virus infection: Resolved and unresolved issues. J Gastroenterol Hepatol 2014; 29: 26-30.
2. Sagnelli E, Pisaturo M, Martini S, et al. Advances in the treatment of hepatitis B virus_hepatitis C virus coinfection. Expert Opin Pharmacother 2014; 15: 1337-1349.
3. Liu CJ, Chuang WL, Lee CM, et al. Peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses. Gastroenterology 2009; 136: 496-504.
4. Chu CJ, Lee SD. Hepatitis B virus_hepatitis C virus coinfection: epidemiology, clinical features, viral infections and treatment. J Gastroenterol Hepatol 2008; 23: 512-520.
5. Bini EJ, Perumalswami PV. Hepatitis B virus infection among American patients with chronic hepatitis C virus infection: prevalence, racial_ethnic differences, and viral interactions. Hepatology 2010; 51: 759-766.
6. Shih CM, Lo SJ, Miyamura T, et al. Suppression of hepatitis B virus expression and replication by hepatitis C virus core protein in HuH-7 cells. J Virol 1993; 67: 5823-5832.
7. Liaw YF, Leung N, Kao JH, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int 2008; 2: 263-283.
8. Kumada H, Toyota J, Okanoue T, et al. Telaprevir with peginterferon and ribavirin for treatmentnaïve patients chronically infected with HCV of genotype 1 in Japan. J Hepatol 2012; 56: 78-84.
9. Hayashi N, Izumi N, Kumada H, et al. Simeprevir with peginterferon_ribavirin for treatment-naïve hepatitis C genotype 1 patients in Japan: CONCERTO-1, a phase III trial. J Hepatol 2014; 61: 219-227.
10. Yu JW, Sun LJ, Zhao YH, et al. Analysis of the efficacy of treatment with peginterferon alpha-2a and ribavirin in patients coinfected with hepatitis B virus and hepatitis C virus. Liver Int 2009; 29: 1485-1493.
11. Yu ML, Lee CM, Chen CL, et al. Sustained HCV clearance and increased HBsAg seroclearance in patients with dual chronic hepatitis C and B during post-treatment follow-up. Hepatology 2013; 57: 2135-2142.
12. Hayashi N, Seto C, Kato M, et al. Once-daily simeprevir (TMC435) with peginterferon_ribavirin for treatment-naïve hepatitis C genotype 1-infected patients in Japan: the DRAGON study. J Gastroenterol 2014; 49: 138-147.